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Homing of allogeneic donor T cells to recipient tissue is imperative for the development of acute graft-versus-
host disease (GVHD) after bone marrow transplantation (BMT). In this study we show that alteration of T cell
homing due to integrin-b7 deﬁciency on T cells or its ligand MAdCAM-1 in BMT recipients contributes to the
pathophysiology of experimental GVHD. In contrast, lack of CC chemokine receptor 9 on donor T cells alters
tissue homing but does not impact GVHD survival. We further demonstrate that MAdCAM-1 is aberrantly
expressed in hepatic murine GVHD as well as in patients with active liver GVHD. However, inﬁltration of
donor T cells in gut but not liver was dependent of MAdCAM-1 expression, indicating, that homing and/or
retention of donor T cells rests on divergent molecular pathways depending on the GVHD target tissue.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION chemokine CCL25 (TECK), respectively, play an important
Graft-versus-host disease (GVHD) remains a major
complication after allogeneic hematopoietic stem cell or
bone marrow transplantation (BMT) [1]. New strategies for
the prevention and treatment of GVHD are urgently needed
to reduce morbidity and mortality after BMT. Key events in
the development of GVHD are the generation of alloreactive
T cells with the potential to home to the main target organs
of acute GVHD skin, gut, and liver [1]. The reason for this
target organ speciﬁcity remains unclear but might be related
to differences regarding local susceptibility to conditioning
regimenetriggered damage [2], localization of T cell priming
sites [3], activation of antigen-presenting cells [4], and
cytokine responses [5].
The integrin-a4b7 (LPAM-1), the CC chemokine receptor 9
(CCR9), and their corresponding ligands, mucosal vascular
addressin cell adhesion molecule 1 (MAdCAM-1) anddgments on page 2078.
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ty for Blood and Marrow Transplantation.role in T cell homing to the intestine under homeostatic
conditions. It has been demonstrated that deﬁciency of
integrin-a4b7 on allogeneic donor T cells leads to reduced
GVHD and prolonged survival after BMT in models of
experimental GVHD [6,7]. In addition, integrin-b7edeﬁcient
donor T cells do not home as efﬁciently to the liver as
compared with integrin-b7þ donor T cells [7]. Despite the
fact that a number of studies suggest a role for CCR9 during
GVHD [8-10], this has not been addressed so far in detail.
Besides the gut, MAdCAM-1 and CCL25 are aberrantly
expressed in the liver during inﬂammation, thereby medi-
ating the recruitment of a4b7þCCR9þ T cells [11]. However,
the contribution of these homing cues has not been exam-
ined during liver GVHD.
Interestingly, the recruitment of mucosal T cells to the
liver might be a causal factor for extraintestinal manifesta-
tions of inﬂammatory bowel disease [12]. Inﬂammatory cy-
tokines such as tumor necrosis factor (TNF)-a can lead to
MAdCAM-1 expression in endothelial cells of the liver [13],
and TNF levels have been shown to be increased during
GVHD [14,15]. The role of CCR9þ T cells during hepatic
A. Schreder et al. / Biol Blood Marrow Transplant 21 (2015) 2069e20782070inﬂammation is less clear, because CCL25was not found to be
induced in liver endothelial cells by inﬂammatory signals or
cytokines [12]. Based on these observations, we hypothe-
sized that the gut-homing axis of integrin-a4b7eMAdCAM-1
and CCR9eCCL25 might be relevant for the pathophysiology
of hepatic GVHD and could therefore represent a therapeutic
target for prevention or treatment of this disease.
In this study we show that integrin-b7 and 1 of its ligands,
MAdCAM-1, contribute to the pathophysiology of experi-
mental GVHD. In contrast, expression of CCR9 on donor
T cells does not impact GVHD survival. We further demon-
strate that MAdCAM-1 is aberrantly expressed in hepatic
GVHD, in mice, and in patients with active liver GVHD.
However, donor T cell homing to the liver is independent of
hepatic MAdCAM-1 expression in experimental GVHD.
METHODS
Animals
Wild-type (WT) C57BL/6 (H-2Kb), B6D2F1 (BDF1, H-2bxd), and BALB/c
(H-2Kd) mice were purchased from Charles River Laboratories (Sulzfeld,
Germany) or bred at the central animal facility of Hannover Medical School
under speciﬁc pathogen-free conditions. C57BL/6 Thy1.1 (H-2Kb), C57BL/6
CCR9/ (H-2Kb) [16], C57BL/6 b7/ (H-2Kb) [17], and C57BL/6 MAdCAM-
1/ [18] were bred at the central animal facility of HannoverMedical School
under speciﬁc pathogen-free conditions.
Antibodies and Flow Cytometric Analysis
Fluorochrome-labeled CD3, CD4, and CD8 antibodies were purchased
from BD Biosciences (Sulzfeld, Germany). The antihuman MadCAM-1 anti-
body (clone 17F5) was purchased from Acris (Herford, Gemany). Acquisition
of ﬂow cytometric data was performed on LSRII (BD Biosciences, San Jose,
CA). FlowJo software (Treestar, Ashland, OR, USA) was used for data analysis.
BMT Graft Preparations and Induction of Acute GVHD
Spleens were dissociated, and cells were ﬁltered before a RBC lysed
lymphocyte suspensionwas prepared. The T cell enrichment was performed
using magnetic microbeads according to the manufacturer’s instructions
(MACS, Pan-T cell isolation kit; Miltenyi Biotec, Gladbach, Germany). Bone
marrow (BM) cells were isolated from femur and tibia. For T cell depletion,
T cells were stained with anti-Thy1.2 biotin (mmT1) and separated by MACS
with streptavidin-magnetic beads (Miltenyi Biotec, Bergisch-Gladbach,
Germany).
The C57BL/6 (H-2b) into BALB/c (H-2d), BALB/c (H-2d) into C57BL/6
(H-2b), or C57BL/6 (H2b) into BDF1 (H2bxd) acute GVHD models were per-
formed as described elsewhere [19-21]. In brief, BALB/c, C57BL/6 or BDF1
mice were lethally irradiated with 800 cGy, 1.100 cGy, or 1.200 cGy,
respectively, from a 137Cs g-source. Donor cells were injected i.v. via tail
vein within 24 hours after irradiation. Recipient mice received 5  106 T cell
MACS-depleted (WT C57BL/6 or WT BALB/c) BM cells and 1  106 MACS-
sorted C57BL/6 T cells (C57BL/6 CCR9/, C57BL/6 b7/) or 3  106 WT
BALB/c T cells. After BMT, mice were given antibiotic therapy via drinking
water (co-trimoxazole; Ratiopharm, Ulm, Germany) for the ﬁrst 21 days.
Mice were monitored for survival daily. Clinical signs of acute GVHD, such as
rufﬂed fur, weight loss (mild > 10% of initial body weight; severe > 25% of
initial body weight), hunched back, inactivity, and diarrhea, were monitored
2 times per week. Severity of each clinical signwas scored (no¼ 0; mild¼ 1;
severe ¼ 2), and animals with a total score > 6 were killed by cervical
dislocation and counted as GVHD lethality. Somemice died without humane
intervention due to severe GVHD.
Assessment of GVHD Target Organ Inﬁltration
GVHD target organs were harvested from recipient mice at 21 days after
BMT, and lymphocytes were isolated for assessment. Lymph nodes and
spleenwere carefullymashed and ﬁltered through a nylonmesh. Isolation of
lamina propria lymphocytes, intraepithelial lymphocytes, and liver lym-
phocytes was performed as described elsewhere [7]. Pooled intraepithelial
lymphocytes and lamina propria lymphocytes were considered as intestinal
lymphocytes.
Histologic Assessment of Acute GVHD
Liver and gut were ﬁxed in 4% formalin, embedded in parafﬁn, and
stained with H&E. Blinded slides were scored by a pathologist, based on
criteria described by Kaplan et al. [22].Patients with GVHD of the Liver
Patients were treated at Hannover Medical School. Liver tissue was
obtained from patients with suspected GVHD of the liver after allogeneic
stem cell or BMT. Control liver tissue was obtained from a patient with focal
nodular hyperplasia in the liver. It was kindly provided by Dr. Jäger,
Department of General Surgery, Hannover Medical School.
Ethics Statement
Patient samples were collected after patients’ written informed consent
and approval by the local research ethics committee of Hannover Medical
School (no. 5003). The study conformed to the ethical guidelines of the
Declaration of Helsinki. All animals were handled in accordance with insti-
tutional and governmental directives and were approved by the Nie-
dersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit
(permit nos. 07/1383 and 11/0619). This study was performed in accordance
with the German Animal Welfare Law and with the European Communities
Council Directive 86/609/EEC for the protection of animals used for experi-
mental purposes.
Competitive In Vivo Homing of Donor T Cells
Single cell suspensions were prepared from spleen and lymph nodes
at day 3 after BMT of C57BL/6 WT or b7/ T cells into BALB/c recipients.
After RBC lysis, cells were labeled with 10 mM 5- (and 6-) Carboxyte-
tramethylrhodamine (TAMRA) or 5 mM Carboxyﬂuorescein succinimidyl
ester (CFSE) (Invitrogen, Carlsbad, CA) for 15 minutes at 37C. Lethally
irradiated BALB/c recipients received BM and Tcell grafts as described above.
Three weeks after BMT, recipient mice received 5  106 labeled WT and
b7/ T cells in a ratio of 1:1 via an i.v injection into the lateral tail vein.
Sixteen hours after transfer, C57BL/6 recipient mice were killed and lym-
phocytes harvested from lymph nodes, spleen, liver, and gut and analyzed
by FACS.
Cytokine Bead Array and Liver Function Tests
Peripheral blood was obtained from mice and the serum separated. The
activities of glutamic oxaloacetic transaminase and glutamic pyruvic
transaminase in the serum of recipient mice were determined with an
Olympus AU 400 analyzer (Beckman Coulter, Inc.; Krefeld, Germany).
Concentrations of inﬂammatory cytokines IFN-g, TNF-a, and CCL2 (MCP-1)
in the sera were quantiﬁed by the mouse inﬂammatory cytokine cytometric
bead array kit (BD Biosciences, San Diego, CA) according to the manufac-
turer’s manual.
RNA Expression Analysis via Quantitative PCR
Total RNA was isolated from snap frozen liver and small and large
intestine of recipient mice 21 days after transplantation using Trizol (Invi-
trogen) or RNeasy RNA Mini Kit (Invitrogen). cDNA was synthesized using
random hexamers from 1 mg DNase-treated RNA. Quantitative PCR was
performed in the light cycler PCR system (Roche, Indianapolis, IN) and
StepOnePlus TM PCR system (Applied Biosystems, Foster City, CA) using
SYBR Premix Ex Taq (TaKaRa; Otsu, Shiga, Japan). The following primers
were used: MadCAM-1 (Fw-M CAGCTTGGGCAGTGTACAGAC; Rev-M
TCTGCAGGCCAGATGTTGTGG) and HPRT (Fw-HPRT, 5-TCCTCCTCAGACC
GCTTTT-3; Rev-HPRT, 5-CCTGGTTCATCATCGCTAATC-3) [23].
MAdCAM-1 Staining of Murine Liver Sections
OCT-embedded mouse liver sections were ﬁxed in cold acetone, rehy-
drated in Tris-buffered saline with 0.05% Tween 20, blocked with 5% mouse
serum, and stained at room temperature for 30 minutes with puriﬁed anti-
mouseMadCAM-1 (MECA-367, homemade) followed by secondary antibody
anti-rat Cy5 that was incubated for 50minutes at room temperature. Finally,
after washing, anti-mouse CD3-PE (17A2, homemade) was added. Nuclei
were visualized by incubation with DAPI. Pictures were taken with a ﬂuo-
rescence microscope (Axiovert) using AxioVision 4.6 software (both from
Carl Zeiss, Inc., Oberkochen, Germany).
b7 Staining of T Cells in Murine Gut Sections
OCT-embedded liver sections were rehydrated in Tris-buffered saline
with .05% Tween and blocked twice with 5% rat serum and 10% Fc-block for
10 minutes. Afterward, slides were blocked with biotin (.01%) and avidin
(.05%) (Sigma-Aldrich, St. Louis, MO) for 15 minutes each with a washing
step in between. The staining of CD4-Alexa488 (clone Rm-CD4-2, home-
made), CD8b-bio (clone Rm-CD8, homemade), and b7-PE (clone M293, BD
Bisosciences, San Diego, CA) was performed at room temperature for
1.5 hours. Slides were washed 2 times with Tris-buffered saline and 1% FCS
and 2 times with Tris-buffered saline. Streptavidin-Cy5 was incubated for
1 hour. The nuclei were visualized by incubation with DAPI. Pictures were
taken using Olympus BX61 and software cellSens Dimensions 1.9 (both from
Olympus, Hamburg, Germany).
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The human liver biopsy sections were deparafﬁnized and treated with
3% H2O2 in MeOH for 10 minutes to inactivate intrinsic peroxidase activity.
The slides were washed with TBS/T buffer and blocked with 10% goat serum
2 times for 30 minutes. To avoid unspeciﬁc staining, a block of biotin (.01%)
and avidin (.05%) was performed for 15 minutes each with a washing step in
between. TheMAdCAM-1 staining was performed in 1:30 dilution overnight
at 4C. An isotype control unspeciﬁc IgG1 antibody (OX7) was used. The
slides were incubated with the secondary goat anti-mouse biotin antibody
at 1:100 dilution (Jackson, West Grove, PA) for 45 minutes and with
streptavidin-POX for 30 minutes. The signal was ampliﬁed with H2O2 acti-
vated diaminobenzidine-tetrahydrochloride according to the manufac-
turer’s manual (Sigma-Aldrich) for 2 minutes at room temperature. Pictures
were taken using Olympus BX61 and software cellSens Dimensions 1.9 (both
from Olympus).Data Analysis and Statistics
Statistical analysis was performed with Prism 4 (Graph-Pad Software,
Inc., La Jolla, CA, USA). Signiﬁcant values were determined using the
nonparametric 2-sided Mann-Whitney test. Statistical differences for mean
values are as follows: *P  .05, **P  .01, and ***P  .001. The analysis of
survival data was performed using Kaplan-Meier estimation and log-rank
test.RESULTS
Expression of b7-Integrin but not CCR9 on Donor T Cells
Contribute to GVHD
To address the impact of integrin-b7 and chemokine re-
ceptor CCR9 on GVHD development, we used integrin-b7/
and CCR9/ mice as T cell donors in a well-established
model of acute GVHD [19]. Phenotypes of both mice have
been well described [16,17]. We performed GVHD experi-
ments with 1 106 C57BL/6 WT or integrin-b7/ (C57BL/6)
donor splenic T cells transferred in parallel to the BM cells.
Recipients of T celledepleted BM were used as controls. As
expected, transfer of integrin-b7/ T cells led to a signiﬁcant
decrease in mortality, compared with WT T cells (Figure 1A).
In line with this result, weight loss (Figure 1B) and clinical
GVHD score (Figure 1C) was lower in recipients of integrin-
b7/ T cells. Next, we performed GVHD experiments with
CCR9/ donor T cells. BALB/c mice that received CCR9/
C57BL/6 donor T cells did not show any survival beneﬁt as
compared with recipients transplanted with WT donor
T cells (Figure 2A). We observed no signiﬁcant difference in
weight loss (Figure 2B) and clinical GVHD (Figure 2C) in re-
cipients of CCR9/ T cells after BMT. There was also no sig-
niﬁcant difference in survival and clinical GVHD score
(Figure 2D,E) using haploidentical BMT recipients (BDF1),
where in general a milder course of GVHD is expected.
However, CCR9/ T cells caused a less pronounced weight
loss as compared with WT T cells (Figure 2F), indicating less
harmful tissue damage.Figure 1. b7 deﬁciency of donor T cells leads to reduced GVHD. Lethally irradiated BA
C57BL/6 WT or integrin-b7 knockout T cells. (A) Survival of BMT recipients was monit
assessed twice per week. (C) Assessment of clinical GVHD scores of recipient mice w
n ¼ 2 for BM without T cells; 1 of 2 independent experiments is shown).To determine the degree of inﬂammation in GVHD, we
measured serum of BALB/c recipient mice at different
time points after BMT. We observed reduced levels of TNF-a
and MCP-1 only at day 21 after transplantation in recipients
of integrin-b7/ T cells when compared with controls
(Figure 2G). However, there was no difference in serum
cytokine levels comparing serum of CCR9/ T cells re-
cipients with controls 7, 14, or 21 days after BMT (Figure 2G).
Next, we performed a detailed histopathologic evaluation
of integrin-b7/- (Figure 3A) and CCR9/- (Figure 3B)
compared with WT recipients 3 weeks after transplantation.
We observed less colonic GVHD not only in recipients of
-b7/ but also in CCR9/ recipients when compared with
WT. This would suggest that weight loss and pathologic score
cannot reliably predict survival changes in the setting of
these GVHD models.
In line with the prolonged survival and histopathology,
recipients of integrin -b7/ T cells showed signiﬁcantly
reduced numbers of CD4þ donor T cells in the intestine
(P ¼ .004) and mesenteric lymph nodes (P ¼ .002). Interest-
ingly, recipients of integrin-b7/ T cells also accumulated
less CD4þ donor T cells the liver (P ¼ .015) when compared
with WT controls (Figure 3C). In contrast, differences were
not apparent regarding CD8þ donor T cells (Figure 3C). We
detected slightly higher accumulation of CD4þ CCR9/
donor T cells in the liver (P ¼ .041) of BMT recipients when
compared with WT controls (Figure 3D). To test whether
reduced or increased liver inﬁltration had an impact on liver
function, we analyzed the serum levels of liver enzymes in
b7/, CCR9/, and WT BMT recipients at 21 days after
transplantation. Reduced CD4þb7/ donor T cell inﬁltration
to the liver was associated with signiﬁcantly reduced serum
glutamic oxaloacetic transaminase levels (P ¼ .028). We did
not observe signiﬁcant differences comparing CCR9/ and
WT recipients (Figure 3E).
From these results we conclude that integrin-b7 expres-
sion on donor T cells contributes to the pathogenesis of
intestinal and hepatic GVHD. In contrast, CCR9 expression
seems to have a subordinate role for donor T cell homing
during acute GVHD.Aberrant Expression of MAdCAM-1 in the Liver after
Allogeneic BMT
To address the reduced accumulation of integrin-b7/
T cells in the liver in the context of acute GVHD, we screened
GVHD target organs for the expression of MAdCAM-1. We
analyzed sections from liver and small and large intestine for
MAdCAM-1 expression using ﬂuorochrome-labeled antibodiesLB/c recipients were transplanted with 5  106 T celledepleted BM and 1  106
ored daily. (B) Mean percentage of starting body weight of BMT recipients was
as performed twice per week (n ¼ 6 per group of WT and b7 knockout group,
Figure 2. CCR9 deﬁciency of donor T cells does not inﬂuence survival after BMT. (A) Lethally irradiated BALB/c recipients were transplanted with
5  106 T celledepleted (TCD) BM and 1  106 C57BL/6 WT or CCR9 knockout (KO) T cells. Survival of BMT recipients was monitored daily. (B) Mean percentage and
standard deviation (SD) of starting body weight of BMT recipients was assessed twice per week. (C) Assessment of clinical GVHD scores of recipient mice was done
twice per week, and mean scores and SD are shown (n ¼ 5 per group of WT and CCR9 KO group, n ¼ 2 for BM without T cells; 1 of 2 independent experiments is
shown). (D) Lethally irradiated BDF1 recipient mice were transplanted with 5  106 TCD BM and 1  106 C57BL/6 WT or CCR9 KO T cells. Survival of BMT recipients
was monitored daily. (E) Mean percentage and SD of starting body weight of BMT recipients was assessed twice per week. (F) Assessment of clinical GVHD scores of
recipient mice was done twice per week, and mean scores and SD are shown (n ¼ 7 per group of WT and CCR9 KO group, n ¼ 2 for BM without T cells; 1 of 2
independent experiments is shown). (G) Levels of inﬂammatory cytokines IFN-g, MCP-1, and TNF-a were measured in the sera of C57BL/6 WT, b7 KO, or CCR9 KO
T cell recipients (BALB/c) at days 7, 14, and 21 after BMT. Bars represent mean values, and error bars show the standard error of the mean. Data were pooled from 2
independent experiments (total n ¼ 6 per group; n ¼ 3 per group in each independent experiment; n ¼ 1 for TCD BM, total n ¼ 2).
A. Schreder et al. / Biol Blood Marrow Transplant 21 (2015) 2069e20782072and immunoﬂuorescence microscopy and quantitative PCR for
expression of MAdCAM-1 mRNA.
As previously described, MAdCAM-1 was expressed in
small intestine (Figure 4A). We did not observe MAdCAM-1
staining in noninﬂamed liver tissue from untreated
C57BL/6 mice (Figure 4B) [24]. However, 3 weeks after BMT
the inﬂamed liver showed expression of MAdCAM-1 in some
endothelial vessel cells in close proximity to areas of
inﬂammation distinguished by substantial T cell inﬁltration
(Figure 4C,D).
To validate these results, we performed quantitative
PCR for MAdCAM-1 transcripts in GVHD target organs. Inline with the results from immunoﬂuorescence micro-
scopy, we detected a 20-fold increase of MAdCAM-1
expression in the liver at 21 days after GVHD induction
when compared with recipients of a BM-only graft
(without T cells). Of note, there was no increase in
MAdCAM-1 expression in the intestine during GVHD
(Figure 4E) beyond the level already existing in non-
manipulated mice. These ﬁndings may explain the reduced
amounts of CD4þ T cells inﬁltrating gut and liver once b7 is
missing on the T cells. In contrast, alternative pathways
seem to exist in case of CD8þ T cells that compensate for
loss of b7-based T cell inﬁltration.
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Figure 3. Reduced accumulation of b7 knockout (KO) donor T cells in target organs of acute GVHD. (A) Histopathology of colon, small intestine (SI), and liver
of WT and integrin-b7 KO or (B) CCR9 KO recipients 21 days after BMT (total n ¼ 5 to 6 per group; n ¼ 2 to 3 per group in each independent experiment; n ¼ 1
for T celledepleted [TCD] BM, total n ¼ 2). (C) Absolute numbers of donor CD4þ and CD8þ T cells in spleen (SPL), mesenteric lymph nodes (mLN), liver, and
the gut of transplanted mice were analyzed on day 21 after BMT. After transplantation with WT or integrin-b7 KO T cells and TCD BM or (D) after trans-
plantation with WT or CCR9 KO T cells and TCD BM. Data were combined from 2 independent experiments. Each dot represents the total cell count derived
from 1 mouse (total n ¼ 6 per group; n ¼ 3 per group in each independent experiment). (E) Liver damage parameters glutamic oxaloacetic transaminase
(GOT) and glutamic pyruvic transaminase (GPT) were measured in the sera of integrin-b7 KO or (F) CCR9 KO recipient mice at day 21 after BMT. Bars indicate
mean values. Error bars show standard error of the mean. Data were pooled from 2 independent experiments (total n ¼ 6 per group; n ¼ 3 per group in each
independent experiment).
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GVHD of the Liver
Because MAdCAM-1 is expressed in the inﬂamed liver of
GVHD mice, we also wanted to test whether we could detect
MAdCAM-1 expression in patients suffering from GVHD of
the liver. We identiﬁed a heterogeneous group of 15 patientswith GVHD of the liver, as proven by liver biopsy and judged
by an expert clinical pathologist. Patient characteristics are
shown in Table 1. Six patients had developed acute GVHD of
the liver, and 4 patients had chronic GVHD of the liver.
Another 5 patients were diagnosed with GVHD of the liver
after administration of donor lymphocyte infusion. Patients
Figure 4. Aberrant expression of MAdCAM-1 in the liver during experimental murine or human GVHD. Expression of MadCAM-1 was visualized using
immunohistochemistry. Healthy mice were analyzed in comparison with GVHD animals at 21 days after transplantation. MAdCAM-1 expression can be
found in Peyers’s patches (PP) in untreated animals (A) but not in healthy liver (B). After induction of GVHD, MAdCAM-1 is expressed in the inﬂamed liver
(C and D). One representative staining of 2 independent experiments is shown (E). Relative expression levels of MadCAM-1 mRNA in liver, small intestine,
and colon at 3 weeks after transplantation was compared with T celledepleted BM recipients using the DDCt method. Hypoxanthine-guanine phosphor-
ibosyltransferase (HPRT) primers were used for the ampliﬁcation of the housekeeping gene. HPRT was used for normalization. (n ¼ 3). Representative data
are shown from 1 of 2 experiments that gave similar results. Data are expressed as mean values  standard error of the mean. (F) Expression of MAdCAM-1 in
liver biopsies in patients suffering from acute, chronic, or postedonor lymphocyte infusion GVHD. MAdCAM-1 expression was visualized using immuno-
histochemistry and DAB signal ampliﬁcation system. Two representative slides are shown in combination with isotype control and 1 patient without GVHD
of the liver. In total, 15 GVHD patient samples and 1 control patient were analyzed.
A. Schreder et al. / Biol Blood Marrow Transplant 21 (2015) 2069e20782074had variable histologic grades of hepatic GVHD. In 12 of 15
patients we were able to show clear MAdCAM-1 expression
on endothelial cells in close proximity to T cell inﬁltrates
(Figure 4F). Interestingly, all 3 patients who did not show
MAdCAM-1 expression in the liver also had no intestinal
GVHD involvement. In the control patient without GVHD we
could detect only subtle MAdCAM-1 expression.MAdCAM-1 Deﬁciency Diminishes Acute GVHD
To test whether expression of MAdCAM-1 contributes to
GVHD pathophysiology, we used MAdCAM-1/ recipients in a
model of experimental GVHD. Here,we had to use another CD4þ
T celletriggered MHC class I and II mismatched model of
experimental GVHD [25]. Recipient mice were C57BL/6 MAd-
CAM-1/ or C57BL/6WT, andBALB/cmicewere used as donors.
Table 1
Characteristics of Patients with Hepatic GVHD
GVHD n Age at
Transplantation
Donor Days after
Transplantation
Gender Disease Histologic Grade
of Liver GVHD
MAdCAM-1
Expression
GVHD Organ Involvement
Gut Skin Other Organs
Acute
1 53 MMUD 173 M OMF Moderate þ No Yes No
2 23 MRD 185 M ALL Moderate þ Yes Yes Yes
3 20 MUD 106 M ALL Mild þ Yes Yes No
4 33 MMUD 176 M MDS Mild þ Yes Yes Yes
5 9 MRD 75 M NHL Mild þ Unknown Unknown Unknown
6 58 MRD 187 F AML Moderate  No No No
Post-DLI
1 28 MUD 742 M NHL Mild  No No No
2 62 MMUD 406 M AML Mild þ No Yes Yes
3 18 MUD 528 M AML Mild þ No No No
4 57 MRD 492 M AML Mild þ/ Yes Yes No
5 33 MUD 2914 M AML Mild þ No Yes Yes
Chronic
1 51 MRD 538 M AML Mild  No Yes Yes
2 52 MRD 471 F MDS Mild þ No No No
3 40 MRD 253 F CML Moderate þ Yes No No
4 56 MMUD 254 F AML Moderate þ Yes Yes No
MMUD indicates mismatched unrelated donor; OMF, osteomyeloﬁbrosis; þ, high MAdCAM-1 expression; MRD, matched related donor; ALL, acute lympho-
blastic leukemia; MUD, matched unrelated donor; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; AML, acute myeloid leukemia; , no
MAdCAM-1 expression; DLI, donor lymphocyte infusion; þ/, low MAdCAM-1 expression; CML, chronic myeloid leukemia.
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mortality from acute GVHD when compared with WT control
recipients (P ¼ .03) (Figure 5A), although weight loss
(Figure 5B) and clinical GVHD score (Figure 5C) were similar
when comparing WT and MAdCAM-1/ recipients. These
results showed that recipient deﬁciency for the expression of
the integrin-a4b7 ligand MAdCAM-1 ameliorated GVHD,
indicating that MAdCAM-1 expression contributes to GVHD
pathophysiology. However, a detailed histopathologic analysis
of main GVHD target organs did not show signiﬁcant differ-
ences when we compared MAdCAM-1/ with WT recipient
mice 3 weeks after BMT (Figure 5D).Hepatic MAdCAM-1 Expression Does Not Contribute to
Donor T Cell Homing to the Liver
We next wanted to clarify whether MAdCAM-1 expres-
sion during GVHD contributes to donor T cell homing into
the liver. To this end, we analyzed numbers of donor T cells
at 21 days after transplantation in GVHD target organs
of MAdCAM-1 deﬁcient BMT recipient mice. We found
that CD4þ donor T cell accumulation in the intestine was
reduced in MAdCAM-1 recipients when compared with WT
controls (P ¼ .025) (Figure 5E). However, the effect seemed
less pronounced when compared with the experiments
described above with b7/ donors. Therefore, we stained
cryosections to detect T cells expressing integrin-b7 in WT
and MAdCAM-1/ recipients 3 weeks after BMT. Interest-
ingly, we detected similar frequencies of b7þ CD4þ and
CD8þ T cells in the inﬂamed gut of (C57BL/6) MAdCAM-1/
and WT recipients (Figure 5F). These observations suggest
that despite an increased MAdCAM-1 expression in liver,
CD4þ T cells inﬁltrate liver using a b7-dependent but
MAdCAM-1eindependent pathway.
In contrast to the experiments with b7-deﬁcient donor
T cells, we could not detect differences in accumulation of
donor T cells in the liver of MAdCAM-1/ recipient mice
(P ¼ .300). In line with the results described above, serum
levels of liver enzymes were also not different comparing
MAdCAM-1/ and WT recipients 3 weeks after trans-
plantation (Figure 5G).To test whether the reduced accumulation of b7-deﬁcient
donor Tcells in the liver in the B6/BALB/c model (Figure 3C)
can be explained by reduced homing via MAdCAM-1 in the
inﬂamed liver, we performed a short-term homing experi-
ment. In this experiment we adoptively transferred primed
and activated allogeneic WT and b7/ T cells into lethally
irradiated allogeneic mice (BALB/c) with active acute GVHD.
Host mice received allogeneic BMT 3 weeks before the
homing experiment to induce MAdCAM-1 expression in the
liver. To test homing of primed donor T cells under these
inﬂammatory conditions of acute GVHD, WT or b7/ T cells
were labeled with either CFSE or TAMRA before adoptive cell
transfer (and vice versa). Mixtures of donor lymphocytes
were adjusted to contain equal T cell numbers and were then
transferred intravenously. Sixteen hours after transfer, we
analyzed the composition of T cells in the liver and the in-
testine. Recovered donor lymphocytes were identiﬁed in
FACS by CFSE or TAMRA ﬂuorescence. The ratio of labeled
b7/ to WT donor T cells revealed that homing to the in-
testine of b7/ donor CD4þ and CD8þ Tcells was reduced. Of
note, therewas no difference in homing of b7/ donor Tcells
in homing to the liver, as compared with WT T cells
(Figure 6). These results illustrate that the observed inﬁl-
tration rates of allogeneic T cells not only depend on the
immigration efﬁciency of the cells but also the capacity of the
organ under scrutiny to retain them. Based on this, we
conclude that the observed differences in the rates of liver
inﬁltrating T cells predominantly reﬂect a deﬁcit to retain
the allogeneic T cells in the organ via a b7-dependent
mechanism.
DISCUSSION
In addition to the intestine and skin, 1 major target organ
of acute GVHD is the liver. GVHD lesions in the liver
frequently cause life-threatening complications, and thus
new therapeutic strategies are urgently needed. Numerous
studies have examined the role of integrins and chemokines
in the development of acute GVHD [6,7,26,27]. Allogeneic
effector T cells arise in the secondary lymphoid organs and
acquire expression of homing receptors, such as integrin-
a4b7 and CCR9 for intestinal homing [14]. It has been shown
Figure 5. MadCAM-1 deﬁciency prolongs survival after allogeneic BMT and leads to reduced accumulation of donor CD4þ T cells in the intestine. (A) Lethally
irradiated C57BL/6 or MAdCAM-1/recipients were transplanted with 5  106 T celledepleted (TCD) BM supplemented with 3  106 T cells from BALB/c donors.
Recipients of 5  106 TCD BM were used as control. Survival of BMT recipients was monitored daily. (B) Mean percentage and standard deviation (SD) of starting body
weight of BMT recipients was assessed twice per week. (C) Assessment of clinical GVHD scores of recipient mice was done twice per week; mean scores and SD are
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home to the intestine and therefore cause less intestinal
GVHD leading to improved survival [7]. The role of CCR9 as a
homing receptor for allogeneic T cells in the setting of acute
GVHD is not clear to date. Multiple studies suggested a role
for CCR9 in gut homing during GVHD [8-10]. Furthermore,
CCR9 antagonists entered clinical studies for the treatment of
inﬂammatory bowel disease and might therefore also be
useful for the treatment of GVHD [28].
To clarify the role of integrin-b7 and chemokine receptor
CCR9 for hepatic GVHD, we used CCR9/ as well as integrin-
b7/ donor T cells and MAdCAM-1/ recipients in different
models of acute GVHD. We show that recipients of integrin-
b7/ donor T cells survived for the time of follow-up with
less weight loss and fewer clinical signs of GVHD as
compared with controls. In contrast, mice receiving CCR9/
T cells had a slightly diminished weight loss and subtle
clinical signs of acute GVHD only in an attenuated GVHD
model, but ﬁnally succumbed to acute GVHD as mice
receiving WT T cells. The ﬁnding that integrin-b7 deﬁciency
of donor T cells led to protection from acute GVHD was not
surprising because this was demonstrated before in other
models of acute GVHD [7]. However, we did not expect that
deﬁciency of CCR9 on donor T cells had no effect on survival
in acute GVHD. Similar to integrin-b7/ T cell recipients,
recipients of CCR9/ T cells showed slightly fewer signs of
histopathologic damage in the colon, which was, in contrast
to b7/recipients, not accompanied by reduced accumula-
tion of donor CD4þ T cells in the gut. Furthermore, we
detected signiﬁcantly more donor T cells in the livers of
CCR9/ recipients as compared with controls. The mecha-
nism that led to increased accumulation of CCR9/ donor
T cells in the liver remains unclear but might be a compen-
satory effect reﬂecting overall shifts of the homing efﬁciency
into disease target tissues. However, the distribution pattern
of CCR9/ donor T cells in GVHD target organs did not lead
to signiﬁcant alteration of survival in 2 different models of
acute GVHD. It might be worthwhile to investigate the role of
CCR9 in a model of chronic GVHDwhere T cell homing might
be more similar to steady-state conditions.
We show that recipients of integrin-b7/ T cells had less
CD4þ donor T cell inﬁltration, not only in the intestine but
also in the liver together with reduced serum levels of liver
enzymes when compared with WT controls. Our detailed
histopathologic analysis detected less damage in the colon of
b7/ recipients, which is also in line with previously pub-
lished results [7]. However, we could not detect histopath-
ologic changes when we analyzed liver tissue 3 weeks after
transplantation. This might be because manifestations of
GVHD in the liver tissue occur late as compared with gut
pathology.
Interestingly, we did not observe differences in accumu-
lation of CD8þ donor T cells late after BMT, which is in line
with a report in which in a CD8 T celletriggered murine
model of acute GVHD, blocking of MAdCAM-1 did not inhibitshown. Data were combined from 2 independent experiments (total n ¼ 10 or 11 per g
(D) Histopathology of colon, small intestine (SI), and liver of WT and MAdCAM-1
independent experiment; n ¼ 1 for TCD BM, total n ¼ 2). (E) Absolute number of dono
and the gut of transplanted mice were analyzed at day 21 after transplantation of BAL
combined from 2 independent experiments. Each dot represents the total cell count
pendent experiment). (F) Expression of CD4, CD8, and integrin-b7 in the gut at day 21
100 CD8 T cells were analyzed for the expression of integrin-b7 (n ¼ 6 mice per g
parameters glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transamina
day 21 after BMT. Bars indicate mean values. Error bars show standard error of the me
n ¼ 3 per group in each independent experiment).liver GVHD [27]. In contrast, our short-term homing experi-
ments showed a decreased homing of b7/CD8þ donor
T cells to the intestine. This indicates that despite decreased
immigration efﬁciency, allogeneic T cells accumulating in the
target organ can be retained efﬁciently or can proliferate
unhindered, thereby masking the deﬁciency in migration.
Under steady-state conditions, the integrin-a4b7 ligand
MAdCAM-1 is not expressed in the liver. Nevertheless, we
demonstrate that MAdCAM-1 is expressed during murine
GVHD in the liver, and in line with this observation, we could
also detect aberrant MAdCAM-1 expression in human sam-
ples of liver GVHD. This expression pattern was similar to
patients with inﬂammatory bowel syndrome and primary
sclerosing cholangitis [12]. Of note, we could not detect
MAdCAM-1 expression in 3 patients with liver GVHD who
lacked GVHD involvement of the intestine.
Aberrant MAdCAM-1 expression on endothelial cells in
the inﬂamed liver in the setting of acute GVHDmight explain
the reduced inﬁltration of the liver by integrin-b7/ donor
T cells in this model of acute GVHD. We speculate that the
tissue damage caused by allogeneic T cells led to activation of
liver endothelial cells and expression of MAdCAM-1 similar
to other chronic inﬂammatory liver diseases [11]. In contrast
to our expectation that aberrant MAdCAM-1 expression
leads to accumulation of gut-tropic donor T cells in the liver,
we could not observe reduced inﬁltration of donor T cells in
the liver of MAdCAM-1/ recipients when compared with
WT BMT recipients. Moreover, using short-term competitive
in vivo homing assays, we did not detect a signiﬁcant dif-
ference in the homing capacity of integrin-b7/ and WT
donor T cells to this organ. This most likely reﬂects the dif-
ferential settings in both experiments, especially the tem-
poral kinetics of T cell reconstitution and migration in GVHD
in dependence on b7 MAdCAM-1 signals. The observed
reduction of CD4þ T cells in the liver of b7/ T cell recipients
in GVHD as opposed to WT-like short-term hepatic homing
of b7/ T cells probably reﬂects a retention defect of b7/
T cells in the liver (as outlined above) or b7/ deﬁciency
might affect the long-term survival of effector Tcells in GVHD
target organs. Our results show that the b7eMAdCAM-1 axis
is of negligible relevance for donor T cell homing to the liver
during acute GVHD. Other integrin interactions (eg, E-cad-
herin, which is the other ligand for b7-integrins [29]) might
be of more relevance for liver GVHD in this setting. We also
tested whether chemokine receptors CCR4 or CXCR3, which
have been described to guide homing of regulatory T cells to
the inﬂamed liver [30], are differentially regulated in b7/
or CCR9/ donor T cells, but this was not the case (data not
shown).
In conclusion, our study shows that MAdCAM-1 is aber-
rantly expressed in hepatic GVHD of mice and patients with
liver GVHD. However, the b7eMAdCAM-1 axis seems to be
ofminor importance for donor Tcell recruitment to the liver in
experimental GVHD. Further studies are needed to clarify the
role of aberrant MAdCAM-1 expression during acute GVHD.roup; n ¼ 5 to 6 per group in each independent experiment; n ¼ 2 for TCD BM).
/ mice 21 days after BMT (total n ¼ 6 per group; n ¼ 3 per group in each
r CD4þ and CD8þ T cells in spleen (SPL), liver, mesenteric lymph nodes (mLN),
B/c donor T cells (þTCD BM) to WT or MAdCAM-1/ recipient mice. Data were
derived from 1 mouse (total n ¼ 6 per group; n ¼ 3 per group in each inde-
post-BMT was visualized using immunohistochemistry. In total, 100 CD4 and
roup; n ¼ 3 per group in each independent experiment). (G) Liver damage
se (GPT) were measured in the sera of MAdCAM-1/ and WT recipient mice at
an. Data were pooled from 2 independent experiments (total n ¼ 6 per group;
Figure 6. Competitive homing of b7 knockout andWT T cells shows decreased
inﬁltration of integrin-b7/ lymphocytes to the intestine but not to the liver
during active GVHD. TAMRA-labeled b7/ lymphocytes and CFSE-labeled WT
lymphocytes, and vice versa, were intravenously injected into BALB/c re-
cipients at 3 weeks after allogeneic transplantation. Sixteen hours later,
labeled lymphocytes were isolated from the intestine and the liver. Labeling
effects were excluded by normalization of the ratio to 1:1 in each staining
group (n ¼ 3). Error bars show standard error of the mean, and bars show the
mean of 2 independent experiments (total n ¼ 6 per group).
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